Overall survival† · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.42 [0.37, 0.48]
418 participants
High
Overall survival · people with cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival† · people with cutaneous melanoma
BRAF inhibitors leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.4 [0.28, 0.57]
925 participants
High
Overall survival† · people with cutaneous melanoma
MEK inhibitors showed no clear difference in overall survival† compared with chemotherapy (low certainty).
1 finding from 1 review
HR 0.85 [0.58, 1.25]
496 participants
Low
Overall survival† · people with cutaneous melanoma
BRAF plus MEK inhibitors leads to lower overall survival† compared with BRAF inhibitors (high certainty).
1 finding from 1 review
HR 0.7 [0.59, 0.82]
1784 participants
High
Overall survival† · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy probably leads to lower overall survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.6 [0.45, 0.81]
324 participants
Moderate
Overall survival† · people with cutaneous melanoma
Biochemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.94 [0.84, 1.06]
1317 participants
High
Overall survival† · people with cutaneous melanoma
Polychemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.99 [0.85, 1.16]
594 participants
High
Overall survival† · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with anti‐CTLA4 monoclonal antibodies (high certainty).
1 finding from 1 review
HR 0.63 [0.6, 0.66]
764 participants
High
Overall survival† · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in overall survival† compared with chemotherapy (low certainty).
1 finding from 1 review
HR 0.81 [0.65, 1.01]
1157 participants
Low